These results demonstrate that the axis of interleukin 12 and gamma interferon provides a survival advantage in vascularized xenografts by delaying or preventing acute vascular rejection caused by ...

an Interleukin-12 (IL-12) immunotherapy, at the 2025 American Association for Cancer Research (AACR) Annual Meeting, April 25th – 30th, in Chicago, IL. GEN-1013, a non-replicating mRNA vector ...

D epartment of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting interleukin (IL)-12, IL-23, or IL-17 were associated with a lower rate of ...

The study, published in The Journal of ImmunoTherapy of Cancer, details how an immunoprotected device near the tumor microenvironment containing cells engineered to locally release interleukin-12 ...

They explained how an immunoprotective device near the tumor microenvironment containing cells engineered to locally release the protein interleukin-12 (IL-12) successfully induces the recruitment of ...

The following is a summary of “Exploration of the association between 91 inflammatory proteins and immune thrombocytopenia: a ...

ATT-01 uses its ATTimmune platform technology, a silica-based, biodegradable scaffold (mesoporous silica rod, MSR), loaded with GM-CSF and CpG to induce differentiation of AML blasts in vitro, a ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

The study, published in The Journal of ImmunoTherapy of Cancer, details how an immunoprotected device near the tumor microenvironment containing cells engineered to locally release interleukin-12 ...